Cargando…
The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) accounts for about 10% to 20% of breast cancers, does not respond to endocrine treatment, and is more aggressive. Two chemotherapy methods suggested include neoadjuvant chemotherapy (NAC), performed before surgery, and adjuvant chemotherapy (AC), perf...
Autores principales: | Dabbagh, Najmeh, Riazi, Hooman, Khayamzadeh, Maryam, Negahi, Alireza, Akbari, Mahnaz, Akbari, Mohammad Esmail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iran University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448446/ https://www.ncbi.nlm.nih.gov/pubmed/36128267 http://dx.doi.org/10.47176/mjiri.36.61 |
Ejemplares similares
-
Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study
por: Akbari, Mohammad-esmaeil, et al.
Publicado: (2022) -
The Relationship of Pre and Early Postnatal Risk Factors with Breast Cancer
por: Akbari, Atieh, et al.
Publicado: (2020) -
Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021) -
Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016) -
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)